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http://dx.doi.org/10.1016/j.ccr.2013.05.008SUMMARYTumor cells can activate platelets, which in turn facilitate tumor cell survival and dissemination. The exact
mechanisms by which platelets promote metastasis have remained unclear. Here, we show that adenine
nucleotides released from tumor cell-activated platelets induce opening of the endothelial barrier to allow
transendothelial migration of tumor cells and thereby promote cancer cell extravasation. We identified the
endothelial P2Y2 receptor, which is activated by ATP, as the primary mediator of this effect. Mice deficient
in P2Y2 or lacking ATP secretion from platelets show strongly reduced tumor cell metastasis. These findings
demonstrate a mechanism by which platelets promote cancer cell metastasis and suggest the P2Y2 receptor
and its endothelial downstream signaling mechanisms as a target for antimetastatic therapies.INTRODUCTION
In various tumor models, it has been demonstrated that pharma-
cological or genetic depletion of blood platelets strongly inhibits
tumor cell metastasis (Camerer et al., 2004; Pearlstein et al.,
1984), and it is now well established that platelets are involved
in tumor cell survival and dissemination (Erpenbeck and Scho¨n,
2010; Gay and Felding-Habermann, 2011; Honn et al., 1992; Jain
et al., 2010). Tumor cells can induce platelet activation through
various mechanisms, and their metastatic potential correlates
with their ability to activate platelets (Borsig et al., 2001; Camerer
et al., 2004; Erpenbeck and Scho¨n, 2010; Im et al., 2004; Nierod-
zik and Karpatkin, 2006; Palumbo et al., 2005; Ruf and Mueller,
2006). Recent clinical data showing a reduced risk of cancer
metastasis under long-term treatment with aspirin at an anti-
platelet dose (Rothwell et al., 2012) have further supported a
role of platelets in promoting tumor metastasis.
Despite the well-established role of platelet-tumor cell interac-
tions in metastasis, the mechanism by which platelets promote
metastasis remains unclear. It has been suggested that plateletsSignificance
Platelets interact with tumor cells during their passage throug
Consistent with this, long-term therapy with low-dose aspirin
metastasis. The mechanisms underlying this platelet function
released from tumor cell-activated platelets acts through P2Y2
and to facilitate extravasation of tumor cells at metastatic sites.
P2Y2 receptors strongly inhibits tumor cell metastasis. Platelet
signaling are therefore potential targets for the prevention of c
130 Cancer Cell 24, 130–137, July 8, 2013 ª2013 Elsevier Inc.shield tumor cells against mechanical destruction by hemody-
namic shear forces or against recognition and lysis by natural
killer (NK) cells (Nieswandt et al., 1999; Palumbo et al., 2005). It
is also possible that mitogenic stimuli or angiogenic factors
released from tumor-activated platelets promote growth of
tumor cells at secondary sites (Boucharaba et al., 2004; Italiano
et al., 2008; Labelle et al., 2011). Most of these protein mediators
are stored in platelet a-granules, while platelet dense granules
contain small molecules, such as ATP, ADP, or serotonin
(Reed, 2004; Ren et al., 2008).
Here, we studied the role of platelet secretion in endothelial
transmigration of tumor cells during metastatic dissemination.
RESULTS
Platelets Stimulate Tumor Cell Transendothelial
Migration In Vitro through Release of Nucleotides
Since platelets potentiate endothelial cell retraction induced by
tumor cells in vitro and in vivo (Crissman et al., 1988; Honn
et al., 1994; Kramer and Nicolson, 1979), we explored whetherh the blood stream and can promote tumor cell metastasis.
, which inhibits platelet function, reduces the risk of cancer
are poorly understood. In this study, we found that ATP
receptors on endothelial cells to open the endothelial barrier
The blockade of ATP release fromplatelets or the ablation of
secretion, endothelial P2Y2 receptors, and their downstream
ancer cell metastasis.
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endothelium. Tumor cells migrated through an endothelial cell
layer, and this ability was enhanced by the presence of platelets
(Figure 1A). The effect of platelets was dependent on the pres-
ence of endothelial cells (Figure S1A available online). Superna-
tants from platelets stimulated by various mouse and human
tumor cells also promoted tumor cell transmigration, whereas
supernatants from unstimulated platelets were without effect
(Figures 1B and S1B). We therefore tested whether mediators
derived from activated platelets were involved. While inhibition
of thromboxane A2 formation by the cyclooxygenase inhibitor
flurbiprofen had no effect, degradation of platelet-derived nucle-
otides, such as ATP and ADP, using apyrase ablated platelet-
dependent facilitation of tumor cell transmigration (Figure 1C),
suggesting an involvement of nucleotides released from plate-
lets. Consistent with this, tumor cells induced a strong release
of ATP from platelet dense granules (Figure 1D), and addition
of ATP or its stable analog ATPgS stimulated tumor cell transmi-
gration per se (Figures 1E and S1C). Platelets were also able to
enhance tumor cell-dependent diffusion of fluorescein isothiocy-
anate (FITC)-labeled dextran over an endothelial cell layer and
to induce a loss of tight interactions of endothelial cells in the
monolayer, effects which were both blocked by apyrase (Figures
1F–1H and S1D). These data indicate that adenine nucleotides
released from dense granules of tumor cell-activated platelets
promote an opening of the endothelial barrier and a transmigra-
tion of tumor cells through the endothelial layer.
Loss of Dense Granule Secretion Blocks Platelet-
Mediated Tumor Cell Transmigration In Vitro
To study the role of dense granule secretion in platelet-facilitated
tumor cell transmigration, we analyzed mice lacking the exocy-
tosis-priming protein Munc13-4, which is required for regulated
exocytosis and is the predominant Munc13 isoform in platelets
(Crozat et al., 2007; Ren et al., 2010). Munc13-4-deficient
mice have normal platelet numbers, platelet integrin aIIbb3 acti-
vation, adhesion to collagen, and an unchanged ability to form
aggregates with tumor cells (Figures S2A–S2E). Furthermore,
thrombin- and tumor cell-induced release of proteins stored in
a-granules, such as the chemokine platelet factor 4 (PF4) or
von Willebrand factor (vWF), was not affected by Munc13-4
deficiency (Figures 2A–2D). In contrast, Munc13-4-deficient
platelets did not release ATP stored in platelet dense granules
in response to thrombin or tumor cells (Figures 2E and 2F) or
U46619 and collagen (Figures S2F and S2G). Importantly,
Munc-13-4-deficient platelets also lost the ability to enhance
transmigration of tumor cells (Figure 2G), indicating a role of
dense granule secretion but not a-granule secretion in platelet-
dependent migration of tumor cells through an endothelial layer.
Reduced Tumor Cell Metastasis in Mice with Defective
Dense Granule Secretion
To test whether platelet dense granule secretion is required for
tumor cell metastasis in vivo, we analyzed tumor growth and
metastasis in wild-type and Munc13-4-deficient mice. While
the growth of primary tumors after subcutaneous injection of
B16F10melanoma (B16) and Lewis lung carcinoma 1 tumor cells
(LLC1) was indistinguishable between wild-type mice and
animals lacking Munc13-4 (Figures 3A and 3B), the number ofmetastases was strongly reduced in Munc13-4-deficient ani-
mals (Figures 3C and 3D). The effect of Munc13-4 deficiency
seemed not to be caused by differences at the primary site of
tumor growth or during intravasation, since reduced metastasis
in Munc13-4-deficient mice was also observed when B16
and LLC1 cells were injected intravenously (i.v.) (Figures 3E
and 3F). We also analyzed metastasis of tumor cells after i.v.
injection in bone marrow chimeras. Irradiated wild-type mice
reconstituted with Munc13-4-deficient bone marrow showed
significantly less metastasis than animals reconstituted with
wild-type bone marrow (Figure S3A), indicating that Munc13-4
deficiency in nonhematopoietic cells did not contribute to
the phenotype. It is unlikely that the inhibition of metastasis
in Munc13-4-deficient mice is due to a defective NK cell
function, which has been shown to involve Munc13-4 (Crozat
et al., 2007), as NK cell dysfunction would rather result in
increased metastasis (Nieswandt et al., 1999; Palumbo et al.,
2005). Consistent with this, NK cell depletion did not affect the
metastasis-reducing effect of Munc-13-4 deficiency (Figures
S3B and S3C).
Platelet-Mediated Facilitation of Tumor Cell
Extravasation and Metastasis Involves P2Y2 Receptors
Given the evidence for a role of platelet-derived adenine
nucleotides in platelet-stimulated tumor cell transmigration and
metastasis in vitro and in vivo, we tested whether receptors of
adenine nucleotides on endothelial cells are involved. Several
purinergic receptors activated by adenine nucleotides are
present on endothelial cells, in particular P2Y1, P2Y2, and P2X4
(Abbracchio et al., 2006). In the murine endothelial cell line Mile
Sven 1 (MS1), in primary mouse pulmonary endothelial cells,
and in human umbilical vein endothelial cells (HUVECs), we
found predominant expression of the metabotropic P2Y2 and
the ionotropic P2X4 receptors, while expression of P2Y1 was
low (Figures S4A–S4C). Neither blockade nor knockdown of
P2Y1 or P2X4 receptors reduced platelet-dependent tumor cell
transmigration in vitro (Figures 4A and 4B). However, endothelial
knockdown of the ATP receptor P2Y2, for which no specific
antagonist is available, significantly reduced platelet-mediated
tumor cell transmigration (Figures 4B and S4D–S4H). This is
consistent with the observation that knockdown of P2Y2 also
blocked the ATP-induced increase in endothelial permeability
and loss of tight interendothelial junctions (Figures S4I–S4K).
We therefore analyzed the ability of tumor cells to open the endo-
thelial barrier, to extravasate into the pulmonary parenchyma,
and to form metastases in mice lacking ATP secretion from
platelets or in animals deficient in P2Y2. Wild-type, Munc13-4-,
and P2Y2-deficient mice did not differ with regard to basal
FITC dextran leakage (Figure S4L). However, within 3 hr after
i.v. injection of FITC-labeled dextran together with B16 cells,
an opening of the endothelial barrier indicated by increased
extravasation of dextran could be observed in the lungs of
wild-type mice (Figures 4C, 4D, and S4M) but not in Munc13-
4- or P2Y2-deficient mice (Figures 4C and 4D). Vascular leakage
was followed by tumor cell extravasation, which reached a
maximum 6–12 hr after i.v.-injection (Figure S4N). Consistent
with a role of endothelial barrier regulation in the extravasation
of tumor cells at metastatic sites, we observed reduced numbers
of extravasating tumor cells after injection of tumor cells intoCancer Cell 24, 130–137, July 8, 2013 ª2013 Elsevier Inc. 131
Figure 1. Platelets Stimulate Tumor Cell Transmigration In Vitro through Release of Nucleotides
(A and B) The indicated murine tumor cells were seeded on murine MS1 microvascular endothelial cells, and tumor cell transmigration was determined in the
absence or presence of platelets (± Plts) (A) or supernatants (supernat.) of platelets preincubated in the absence ( stim.) or presence of tumor cells (+ stim.) (B)
(n = 5).
(C) Effect of the COX-inhibitor flurbiprofen (Flurbipr., 100 nM) or the ATP/ADP-degrading enzyme apyrase (Apyr., 20 U/ml) on platelet (Plts)-dependent stimulation
of B16 cell transendothelial migration (n = 5).
(D) Release of ATP from platelets (Plts) alone, B16 cells (TC) alone, or a mixture of tumor cells and platelets (1:100) in the absence or presence of apyrase
(Apyr., 20 U/ml).
(E) Effect of the stable ATP analog ATPgS (10 mM) on transendothelial migration of B16 cells (n = 5).
(F) Effect of B16 cells (TC) and platelets (Plts) alone or together in the absence and presence of apyrase (Apyr., 20 U/ml) on the permeability of an MS1 endothelial
cell layer as determined by permeability for FITC-dextran (n = 5).
(legend continued on next page)
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Figure 2. Loss of DenseGranule Secretion BlocksPlatelet-Mediated
Tumor Cell Transmigration In Vitro
(A–F) Effect of thrombin (A, C, and E) or tumor cells (B, D, and F) on release of
PF4 (A and B), vWF (C and D), or ATP (E and F) fromwild-type (WT), Munc13-4-
deficient platelets (KO) (n = 3–5), or in the absence of platelets ( Plts).
(G) Effect of WT and Munc13-4-deficient platelets (KO) on transendothelial
migration of B16 (left panel) and LLC1 tumor cells (right panel) (n = 5). Shown
are mean values ± SD (A–F) or SEM (G); *p < 0.05; **p < 0.01; ***p < 0.001;
n.s., not significant.
See also Figure S2.
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correlated with the reduced occurrence of metastases in
Munc13-4-deficient mice (Figure 3). Moreover, also absence of(G and H) Morphology of MS1 endothelial cells exposed to supernatants from B
presence of apyrase (Apyr.). Cells were stained for vascular endothelial-cadherin
cellular junctions was determined (G) (n = 4). Boxes in (H) indicate enlarged area
SEM (A–C, E, and F); *p < 0.05; **p < 0.01; ***p < 0.001.
See also Figure S1.P2Y2 strongly reduced the occurrence of metastases when
mice injected with B16 or LLC1 cells were compared with wild-
type mice (Figures 4G and 4H). We further analyzed the role of
P2Y2 in platelet-dependent metastasis using bone marrow
chimeras. While wild-type mice transplanted with wild-type
bone marrow showed the same number of metastases after
i.v. injection of B16 melanoma cells as wild-type mice trans-
planted with P2Y2-deficient bone marrow, P2Y2-deficient mice
transplanted with wild-type bone marrow showed strongly
reduced metastasis. This effect was not further reduced in
P2Y2-deficient mice transplanted with Munc13-4-deficient
bone marrow (Figure S4O), consistent with the notion that
P2Y2 and Munc13-4 operate in the same pathway.
DISCUSSION
The interaction of tumor cells with their microenvironment has
been recognized as an important factor in tumor metastasis
(Chaffer and Weinberg, 2011; Joyce and Pollard, 2009; Nguyen
et al., 2009). Here, we provide evidence that platelet dense
granule secretion of adenine nucleotides in the microenviron-
ment of tumor cells is required for efficient tumor cell extravasa-
tion and formation of metastasis and that this involves activation
of endothelial purinergic P2Y2 receptors by ATP. Thus, besides
their role in promoting tumor cell survival in the circulation and
inducing a prometastatic phenotype, our study shows that
platelets actively enhance tumor cell migration across the endo-
thelial cell layer. This is consistent with the close association of
platelets with metastasizing tumor cells during the first hours
after vascular arrest (Crissman et al., 1988; Im et al., 2004) and
with the ability of platelets to increase vascular permeability
and to promote extravasation of various other cell types (Diac-
ovo et al., 1996; Honn et al., 1994; Petri et al., 2010).
Our data indicate that platelets promote tumor cell extravasa-
tion at early stages after vascular arrest, a critical time period
in which the endothelial barrier has to be opened to allow
tumor cells access to the underlying basement membrane.
Endothelial P2Y2 receptors activated by platelet-derived
adenine nucleotides appear to mediate this process by coupling
to the G-proteins Gq/G11 (Abbracchio et al., 2006). Activation of
the Gq/G11-mediated pathway resulting in an elevation of
intracellular [Ca2+] and activation of protein kinase C has been
shown to induce opening of the endothelial barrier (Gavard and
Gutkind, 2008; Knezevic et al., 2009; Korhonen et al., 2009)
and thereby can facilitate the localized migration of tumor cells
through the endothelium. This is also supported by observations
indicating a role of the endothelial P2Y2 receptor in promoting
transendothelial migration of neutrophils (Kukulski et al., 2010).
It is likely that, in addition to ATP, other platelet-derived factors,
such as transforming growth factor b, promote, in particular,
later stages of tumor cell extravasation (Labelle et al., 2011)
and that this process also involves other bone marrow-derived
cells (Labelle and Hynes, 2012).16 cells alone or B16 cells incubated with platelets (Plts) in the absence and
(red), F-actin (green), and cell nuclei (blue). The percentage of discontinuous
s at the bottom. Bar length: 5 mm. Shown are mean values ± SD (D and G) or
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Figure 3. Reduced Tumor Cell Metastasis in Mice with Defective
Dense Granule Secretion
(A–D) B16 (A and C) or LLC1 cells (B and D) were injected subcutaneously in
the flank of WT or Munc13-4-deficient mice (KO). After 21 days, animals were
sacrificed, primary tumor weight was determined (A and B), and lungs of an-
imals were histologically analyzed for the occurrence of metastases. Total
number as well as the number of small (diameter: <0.1 mm), medium-sized
(diameter: 0.1–1.0 mm), or large (diameter: >1.0 mm) lung metastases was
determined (n = 7–10) (C and D).
(E and F) B16 (E) or LLC1 cells (F) were injected i.v. into WT or Munc13-4-
deficient mice (KO), and 12 days later, lung metastases were evaluated as in
(B) and (D) (n = 6–10). The images show representative lung surface metas-
tases (E) or stained lung sections (F) fromWTorMunc13-4-deficient mice (KO).
Bar length: 100 mm. Arrowheads indicate metastases. Shown are mean
values ± SD; *p < 0.05; **p < 0.01.
See also Figure S3.
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lar prevention trials provided evidence for a reduced risk for
cancer metastasis in patients taking aspirin at doses sufficient
to inhibit platelet function (Rothwell et al., 2012). However,
despite the evidence for a role of platelets in tumor metastasis,
clinical trials have been rare, due to concerns that antiplatelet
drugs affect normal platelet function, leading to bleeding
complications (Erpenbeck and Scho¨n, 2010; Gay and Feld-
ing-Habermann, 2011). The identification of mechanisms
involved in platelet-dependent metastasis downstream of
platelets provides a basis for new approaches to interfere
with platelet-dependent tumor cell dissemination without
affecting physiological platelet functions. Given the central
role of endothelial P2Y2 receptors in mediating the prometa-
static effects of platelet-derived nucleotides, blockade of
P2Y2 or endothelial downstream signaling pathways may serve
as a target to develop novel strategies to prevent tumor cell
metastasis.
EXPERIMENTAL PROCEDURES
Transwell Assay
MS1 cells (8 3 103 at seeding in 50 ml) or HUVEC (6 3 103 at seeding in 50 ml)
were cultured for 2 days on 96 transwell plates with polyester membranes of
8 mm pore size (Corning) with medium changes every day. For knockdown
experiments, 4 3 105 MS1 cells were transfected using Amaxa Nucleofector
Kit V with different sets of small interfering RNA (siRNA) (QIAGEN) against
different P2X and P2Y receptors and 1.2 3 104 cells in 50 ml were seeded to
the upper compartment. Where indicated, MS1 cells were preincubated
with 5-BDBD (1 mM) or MRS2500 (100 nM) for 30 min. Before the experiment,
exemplary wells of each condition were visually checked by calcein-acetoxy-
methyl (AM) staining of the endothelial monolayer, and only wells with 100%
confluency were used. For transmigration, the medium from the upper
compartment was removed and 50 ml of a 1:1 mixture of platelets (2 3 108/
ml) with calcein-AM-labeled tumor cells (8 3 105/ml) in Tyrode’s buffer (TB)
was added to the upper compartment alone or with ATP or ATPgS (10 mM),
flurbiprofen (100 nM), or apyrase (20 U/ml). For supernatant experiments,
human platelets (5 3 107/ml) or mouse platelets (2 3 108/ml) were incubated
for 30 min at 37C alone or with tumor cells (1.6 3 106/ml) and centrifuged
at 350 3 g for 10 min. The supernatant was mixed 1:1 with TB (for MS1 cells)
or cell culture medium (for HUVEC) containing calcein-AM-labeled tumor cells
(8 3 105/ml), and 50 ml were added to the upper compartment. In all experi-
ments, 250 ml TB or culture medium were added to the lower compartment,
and tumor cells were allowed to transmigrate overnight. On the next day, the
nontransmigrated tumor cells from the upper compartment were removed
and only the transmigrated tumor cells on the lower side of the filter or the
bottom of the transwell were imaged (Zeiss Axio Observer.Z1 and Olympus
IX81) and quantified with ImageJ (NIH). Each experiment was performed at
least three times with a minimum of five wells per condition. Experiments
with human platelets were performed according to the regulations of the
local ethics committee of the Hessian Regional Medical Board, and informed
consent was obtained from all subjects.
Endothelial Barrier
The permeability assay was performed as described for the transwell assay,
with some modifications. Briefly, MS1 or HUVEC cells were cultured on
transwell filters and the supernatant of platelets alone or stimulated with tumor
cells wasmixed 1:1with TB or endothelial growthmedium 2 (EGM2) containing
2 mg/ml 70 kDa FITC-dextran (DX), of which 50 ml were added to the upper
compartment in absence or presence of apyrase (20 U/ml). Alternatively,
PBS or ATP (10 mM) was added to the upper compartment. Two hundred fifty
microliters TB or EGM2 were added to the lower compartment. After 90 min,
the amount of passed FITC-DX to the lower compartment was measured
(FlexStation3, Molecular Devices). For visualization of changes in the endothe-
lial barrier, cells were grown on coverslips and stimulated as described above.
Figure 4. Platelet-Mediated Facilitation of Tumor Cell Extravasation and Metastasis Involves P2Y2 Receptors
(A) Effect of the P2X4 receptor antagonist 5-BDBD (1 mM) and of the P2Y1 antagonist MRS2500 (100 nM) on platelet-stimulated transendothelial migration of B16
cells (n = 5).
(B) Endothelial cells were transfected with control siRNA or with siRNAs directed against the messenger RNAs encoding P2Y1, P2Y2, or P2X4. Thereafter,
transmigration of B16 cells was determined in the absence or presence of platelets (± Plts) (n = 5).
(C and D) FITC-dextran extravasation in the lungs of WT, Munc13-4-deficient (Munc13-4 KO), or P2Y2-deficient (P2Y2 KO) mice 3 hr after i.v. injection of buffer or
B16 cells. Shown in (C) are representative images of lung sections stained for CD31 (red) or cell nuclei (blue). Extravasation sites of FITC-dextran (FITC-DX; green)
are indicated by arrowheads; bar length: 10 mm. The bar diagram (D) shows a quantification of extraluminal FITC-positive sites (n = 4).
(E and F) Extravasation of CFSE-labeled B16 cells in the lungs ofWT,Munc13-4-deficient (Munc14-3 KO), or P2Y2-deficient (P2Y2 KO)mice 6 hr after i.v. injection.
Shown are, in (E), representative images of lung sections stained for CD31 (red) or cell nuclei (blue); B16 cells are in green; bar length: 10 mm. The numbers of
extravasating tumor cells per 10 mm2 area of sectioned lung surface are shown in (F) (n = 9–10).
(G and H) B16 (G) and LLC1 cells (H) were injected i.v. in WT and P2Y2-deficient mice (KO), and 12 days later, lung metastases were analyzed histologically
(n = 7–10). Shown are mean values ± SD (G and H) or SEM (A, B, D, and F); *p < 0.05; **p < 0.01; ***p < 0.001; n.s., not significant.
See also Figure S4.
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imaging.
Tumor Models
Mice (at 8–10 weeks of age) were anesthetized with isoflurane (Abbot Labora-
tories), and 1 3 106 B16F10 or LLC1 cells in 100 ml PBS were injected subcu-
taneously to their flanks. Mice with B16 primary tumor were sacrificed 19 days
and mice with LLC1 tumor 21 days after injection of tumor cells, and tumors
were weighed. For analysis of pulmonary metastases, lungs were removed
and fixed in paraformaldehyde, cut in 5 mm sections, and stained for hematox-
ylin and eosin. One section every 200 mm throughout the whole lung was
screened histologically, and the number of metastases was counted and
assigned to the respective size category: small (diameter: <0.1 mm), medium
(diameter: 0.1–1.0 mm) or large (diameter: >1.0 mm). Alternatively, 125 ml of
unlabeled (or 5-[and 6]-carboxyfluorescein diacetate succinimidyl ester
[CFSE]-labeled) tumor cells (5 3 104 cells) were injected to the lateral tail
vein of mice (or retro-orbitally), and lung metastases or single tumor cells
were analyzed 12 days (or 1–24 hr) later. Before processing for immunostaining
(platelet endothelial cell adhesion molecule 1 [PECAM1]) and imaging, animals
were perfused with PBS and paraformaldehyde (day 12) or lungs were
removed and directly fixed in paraformaldehyde (1–24 hr). For quantification
of extravasating tumor cells, cryosections were analyzed in XYZ views on a
Leica SP5 confocal microscope by two criteria: tumor cells directly sur-
rounded by PECAM1 staining (i.e., blood vessel) and with a noninvasive
phenotype (i.e., round cell shape) were scored as intravascular, while cells
outside blood vessels with an invasive phenotype (i.e., irregular cell shape
with protrusions) were scored as extravascular. All experimental animal
procedures were approved by the Regierungspra¨sidia Darmstadt and
Karlsruhe and conform to the relevant regulatory standards.
Analysis of Endothelial Barrier Function In Vivo
One hundred microliters of lysine-fixable 70 kDa FITC-dextran (15 mg/kg) in
PBS was injected i.v. into anesthetized mice. One minute later, 1 3 105 B16
tumor cells in 125 ml PBS were injected i.v. After 1–24 hr, animals were sacri-
ficed, lungs were excised, directly fixed in paraformaldehyde, cryopreserved
in 30% sucrose, and further processed for immunostaining and imaging.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.ccr.2013.05.008.
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